Hasil Pencarian - Baiyong Li

  • Menampilkan 1 - 20 hasil dari 20
Perbaiki Hasil
  1. 1
    Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed

    Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed oleh Tailong Qu, Baiyong Li, Yifei Wang

    Diterbitkan 2022-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity

    Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity oleh Xinghua Pang, Zhaoliang Huang, Tingting Zhong, Peng Zhang, Zhongmin Maxwell Wang, Michelle Xia, Baiyong Li

    Diterbitkan 2023-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity

    Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity oleh Yu Xia, Baiyong Li, Zhongmin Maxwell Wang, Tingting Zhong, Zhaoliang Huang, Xinghua Pang, Tailong Qu, Chunshan Jin

    Diterbitkan 2022-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    427 Efficacy and safety of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with platinum-resistant/refractory epithelial ovarian cancer in a Phase 1 study

    427 Efficacy and safety of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with platinum-resistant/refractory epithelial ovarian cancer in a Phase 1 study oleh Yu Xia, Charlotte Lemech, Xiaoping Jin, Jermaine Coward, Anna Mislang, Baiyong Li, Kon Yew Kwek, Yiting Zhou, Max Wang

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    1194 Mechanism of action of ivonescimab (AK112/SMT112): a first-in-class tetravalent Fc-silent bispecific antibody with dual blockade of PD-1 and VEGF that promotes cooperative biological effects

    1194 Mechanism of action of ivonescimab (AK112/SMT112): a first-in-class tetravalent Fc-silent bispecific antibody with dual blockade of PD-1 and VEGF that promotes cooperative bio... oleh Baiyong Li, Tingting Zhong, Zhaoliang Huang, Xinghua Pang, Chunshan Jin, Xinrong He, Jose Montoya, Betty Chang, Michelle Xia, Jing Min

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    289 Cadonilimab, an anti-PD1/CTLA4 bi-specific antibody with Fc effector null backbone

    289 Cadonilimab, an anti-PD1/CTLA4 bi-specific antibody with Fc effector null backbone oleh Na Chen, Xiaoping Jin, Baiyong Li, Dennis Xia, Tingting Zhong, Zhaoliang Huang, Xinghua Pang, Xinrong He, Zhongmin Wang, Xu Xia

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study

    Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind,... oleh Christopher John Wynne, Alexandra Cole, Charlotte Lemech, Guoqin Wang, Yu Zhang, Benchao Chen, Max Wang, Baiyong Li, Michelle Xia, Rodney Sinclair

    Diterbitkan 2023-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events

    Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events oleh Zhaoliang Huang, Xinghua Pang, Tingting Zhong, Tailong Qu, Na Chen, Shun Ma, Xinrong He, Dennis Xia, Max Wang, Michelle Xia, Baiyong Li

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    266 AK117, a CD47 blocking antibody with robust macrophage activation without red blood cell hemagglutination

    266 AK117, a CD47 blocking antibody with robust macrophage activation without red blood cell hemagglutination oleh Na Chen, Xiaoping Jin, Baiyong Li, Dennis Xia, Tingting Zhong, Zhaoliang Huang, Xinghua Pang, Tailong Qu, Chunshan Jin, Xinrong He, Zhongmin Wang, Xu Xia

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Preclinical imaging evaluation of a bispecific antibody targeting hPD1/CTLA4 using humanized mice

    Preclinical imaging evaluation of a bispecific antibody targeting hPD1/CTLA4 using humanized mice oleh Xingguo Hou, Song Liu, Ziqing Zeng, Zilei Wang, Jin Ding, Yan Chen, Xiangyu Gao, Jianghua Wang, Guanxi Xiao, Baiyong Li, Hua Zhu, Zhi Yang

    Diterbitkan 2024-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Population pharmacokinetic/pharmacodynamic analysis of AK111, an IL-17A monoclonal antibody, in subjects with moderate-to-severe plaque psoriasis

    Population pharmacokinetic/pharmacodynamic analysis of AK111, an IL-17A monoclonal antibody, in subjects with moderate-to-severe plaque psoriasis oleh Qian Li, Ju Qiao, Hongzhong Jin, Benchao Chen, Zhimei He, Guoqin Wang, Xiang Ni, Max Wang, Michelle Xia, Baiyong Li, Rui Chen, Pei Hu

    Diterbitkan 2022-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    384 A Phase 1 study to evaluate the safety, PK, and antitumor activity of AK117, an anti-CD47 monoclonal antibody, in subjects with relapsed/refractory advanced or metastatic solid tumors or lymphomas

    384 A Phase 1 study to evaluate the safety, PK, and antitumor activity of AK117, an anti-CD47 monoclonal antibody, in subjects with relapsed/refractory advanced or metastatic solid... oleh Yu Xia, Hui Gan, Xiaoping Jin, Amy Prawira, Jermaine Coward, Anna Mislang, Adnan Nagrial, Baiyong Li, Zhongmin Maxwell Wang, Kon Yew Kwek, Dennis Xia

    Diterbitkan 2020-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors

    Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors oleh Wenjing Wang, Yu Xia, Charlotte Lemech, Adnan Nagrial, Baiyong Li, Zhongmin Maxwell Wang, Sophia Frentzas, Anna Rachelle Austria Mislang, Craig Underhill, Jermaine I G Coward

    Diterbitkan 2024-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    430 A phase 1b/II clinical study of AK112, a PD-1/VEGF bispecific antibody, in combination with olaparib in BRCA germline wild-type platinum sensitive recurrent ovarian cancer

    430 A phase 1b/II clinical study of AK112, a PD-1/VEGF bispecific antibody, in combination with olaparib in BRCA germline wild-type platinum sensitive recurrent ovarian cancer oleh Li Wang, Rong Li, Guiling Li, Yunxia Li, Kun Song, Yu Xia, Xiaoping Jin, Baiyong Li, Lingying Wu, Bairong Xia, Ruifang An, Yaqing Chen, Huiling Huang, Hongying Yang, Yuzhi Li

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    Ebronucimab in Chinese patients with hypercholesterolemia---A randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimab

    Ebronucimab in Chinese patients with hypercholesterolemia---A randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimab oleh Yanyan Zhang, Zhaohui Pei, Beijian Chen, Yanling Qu, Xiaolin Dong, Binge Yu, Guoqin Wang, Fang Xu, Dongmei Lu, Zhimei He, Benchao Chen, Lei Ma, Max Wang, Baiyong Li, Michelle Xia, Bo Zheng, Yong Huo

    Diterbitkan 2024-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    Fc–Fc interactions and immune inhibitory effects of IgG4: implications for anti-PD-1 immunotherapies

    Fc–Fc interactions and immune inhibitory effects of IgG4: implications for anti-PD-1 immunotherapies oleh Hui Wang, Yu Xia, Meng Su, Baiyong Li, Xingxing Chen, Weifeng Zhang, Xueling Chen, Jirui Li, Xiaomiao Yan, Han Zha, Xiaonan Ma, Chanyuan Zhao, Liangli Hong, Penghao Li, Yanyu Ling, Wenhui Zhao, Tianjing Zheng, Jiang Gu

    Diterbitkan 2024-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial

    The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical tri... oleh Qian Qiao, Chun Han, Sisi Ye, Juan Li, Guoliang Shao, Yuxian Bai, Aibing Xu, Meili Sun, Wei Wang, Jian Wu, Ming Huang, Lijie Song, Luke Huang, Ting Liu, Wei Liu, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Li Bai, Li Bai

    Diterbitkan 2023-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trialResearch in context

    AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II tr... oleh Yuanyuan Zhao, Gang Chen, Jianhua Chen, Li Zhuang, Yingying Du, Qitao Yu, Wu Zhuang, Yanqiu Zhao, Ming Zhou, Weidong Zhang, Yu Zhang, Yixin Wan, Wenting Li, Weifeng Song, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Yunpeng Yang, Wenfeng Fang, Yan Huang, Li Zhang

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study

    Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study oleh Xiaozhong Chen, Wei Wang, Qingfeng Zou, Xiaodong Zhu, Qin Lin, Yi Jiang, Yan Sun, Liangfang Shen, Lin Wang, Guorong Zou, Xiaoyan Lin, Shaojun Lin, Minying Li, Ying Wang, Ruilian Xu, Rui Ao, Rensheng Wang, Haifeng Lin, Shuang Huang, Tingting Xu, Wenting Li, Mengying Xia, Yu Xia, Zhongmin Wang, Baiyong Li, Jingao Li, Chaosu Hu

    Diterbitkan 2024-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201)

    Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201) oleh Yuqin Song, Keshu Zhou, Chuan Jin, Zhengzi Qian, Ming Hou, Lei Fan, Fei Li, Kaiyang Ding, Hui Zhou, Xiaoling Li, Bing Chen, Xiuhua Sun, Xianmin Song, Ming Jiang, Qingyuan Zhang, Lihong Liu, Guohua Yu, Yu Hu, Zheng Zhao, Ligen Liu, Hongwei Xue, Jun Luo, Bai He, Xiaoping Jin, Min Zhao, Baiyong Li, Yu Xia, Jun Zhu

    Diterbitkan 2022-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: